A Practical Guide to CRISPR-Mediated Gene Tagging with a Bioluminescent Peptide

  • Learn about a simple and efficient method for CRISPR-mediated HiBiT tagging that requires no molecular cloning steps, taking you from gene editing to assaying endogenous biology in as little as 24 hours

Summary

Using CRISPR-Cas9 technology, double-strand break (DSBs) can be created at almost any genomic location of interest. Following the DSB, cellular repair machinery can either undergo non-homologous end joining (NHEJ) creating knockouts, or, if a donor DNA template is provided, the cell can undergo homology directed repair (HDR) to knock-in a precise modification or insertion. Often researchers may want to knock-in a tag sequence, enabling further study of protein biology under endogenous regulatory conditions. Compared to ectopic expression of a tagged protein, endogenous locus expression will eliminate overexpression artifacts, mislocalization and aberrant signaling, providing a better understanding of native protein biology. However, many existing protein tags are large making CRISPR-mediated knock-in an inefficient process. In addition antibody-based detection methods and low sensitivity make many protein tags undesirable for use as endogenous tags. Recently, the HiBiT bioluminescent protein tagging system was developed, providing a tagging option that is amenable to CRISPR-mediated gene tagging due to the small 11 amino acid tag size, great sensitivity and simple antibody-free detection methods. In this webinar, we will walk you through a simple and efficient method for CRISPR-mediated HiBiT tagging that requires no molecular cloning steps, taking you from gene editing to assaying endogenous biology in as little as 24 hours.


Speaker

marie-schwinn-125x125

Marie Schwinn, PhD
Senior Research Scientist

Dr. Schwinn is a member of the cell biology team within the Advanced Technologies Group at Promega where she has helped develop luciferase-based technologies for studying intracellular protein interactions, abundance, and post-translational modifications.  Most recently, she has focused on combining these technologies with CRISPR/Cas9 to study protein dynamics at the endogenous level.  Prior to joining Promega, Dr. Schwinn earned her doctorate in Biochemistry from the University of Wisconsin-Madison in the lab of Dr. Hector F. DeLuca, and she received post-doctoral training from Dr. Donna M. Peters in the Department of Pathology and Laboratory Medicine. 

We love to talk science.

Sign up to receive monthly invitations to our webinars.

Sign Up